🏗️ This expansion will double their manufacturing space and enhance sterile injectable drug production.
💰 The project, supported by a £4.3 million grant, aims for a £26 million investment over three years.
🔧 It includes automated GMP production lines, increasing production capacity significantly.
📈 CEO Colin MacKay emphasizes its importance for future growth and client services.
Introduction:
The article details the recent acquisition of a new bioprocess facility by Symbiosis Pharmaceutical Services in Stirling, Scotland, aimed at enhancing their manufacturing capabilities and improving service delivery for sterile injectable drug products.
- Symbiosis Pharmaceutical Services has purchased a new facility in Stirling, Scotland, which will double their manufacturing footprint to 43,500 ft2.
- The acquisition is supported by a £4.3m ($5.5m) grant from Scottish Enterprise and is part of a larger £26m ($34.2m) investment to foster company growth.
- The new facility will feature two automated cleanroom-based GMP production lines, increasing aseptic fill/finish manufacturing capacity and allowing for larger batch sizes up to 15,000 vials.
- Automation technologies will enhance operational flexibility and efficiency in drug manufacturing processes, supporting a diverse range of drug modalities.
- The CEO of Symbiosis, Colin MacKay, indicates that this expansion will significantly improve their global manufacturing capacity, ensuring continued growth and value creation for clients and shareholders.
Conclusion:
Symbiosis’s strategic acquisition of new manufacturing capabilities positions the company for substantial operational growth, increased service capacity, and enhanced client relationships within the biopharmaceutical sector. The integration of advanced automation alongside a significant financial commitment reflects Symbiosis’s commitment to innovation and competitiveness in the global market.
